3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 10 points (0.1%) at 14,085 as of Thursday, Feb. 28, 2013, 12:04 PM ET. The NYSE advances/declines ratio sits at 1,607 issues advancing vs. 1,243 declining with 160 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is up 0.2%. A company within the sector that fell today was Thermo Fisher Scientific ( TMO), up 0.4%. Top gainers within the sector include Amgen ( AMGN), up 1.9%, Express Scripts ( ESRX), up 1.7%, DaVita HealthCare Partners ( DVA), up 1.4%, HCA Holdings ( HCA), up 1.1% and Sanofi ( SNY), up 1.0%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Shire ( SHPG) is one of the companies pushing the Health Care sector lower today. As of noon trading, Shire is down $2.09 (-2.2%) to $94.01 on average volume Thus far, 153,067 shares of Shire exchanged hands as compared to its average daily volume of 316,500 shares. The stock has ranged in price between $93.82-$94.93 after having opened the day at $93.87 as compared to the previous trading day's close of $96.10.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals, Human Genetic Therapies, and Regenerative Medicine. Shire has a market cap of $17.9 billion and is part of the drugs industry. The company has a P/E ratio of 24.3, above the S&P 500 P/E ratio of 17.7. Shares are up 3.4% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Shire Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead